PRESS RELEASES
BLOG
Andrew A. Radin, twoXAR CEO
January 21, 2021
Every year, for the past 39 years, the J.P. Morgan Healthcare Conference has been one of the most reliable predictors of our industry’s health. It’s a gauge of industry innovation, deal making, funding and overall sentiment about the value of the pharmaceutical market.
However, this year was obviously different. We were faced with unprecedented economic decline and an industry seemingly entirely focused on COVID-19. Expectations were tempered for a lot of companies as to what impact this pandemic and this economy will have on funding new pharmaceutical innovation..read post here.
Andrew A. Radin, twoXAR CEO
December 16, 2020
Without a doubt, 2020 has been a trying year. The pandemic has touched every business and every human on earth in different ways. And despite all of its tragic outcomes, it has starkly reminded me that we work in one of the most exciting and innovative industries in the world — the life sciences industry.
I am writing this at a time when the US FDA has just issued an emergency use authorization for a vaccine using new technology, against a new pathogen. We are also just days away from another potential FDA vaccine approval. All of this happened in only a few months and it’s remarkable. Although we do not work in vaccines or pathogenic diseases, and I’ve discussed why in a recent post, I feel more energized than ever to be a part of an industry that can make this happen...read post here.
Andrew A. Radin, twoXAR CEO
October 28, 2020
I recently authored an article for MedCity News discussing the hype surrounding AI, especially as it relates to fighting COVID-19. Since the very beginning of this pandemic, researchers and pharmaceutical companies have been working around the clock to find treatments and, more importantly, develop a vaccine. And, as usual, there has been a plethora of media articles and peer-reviewed journal publications discussing how AI can support these efforts. A lot of that is driven by AI companies themselves, or companies that apply AI to discover treatments...read post here.
Aaron Daugherty, VP Discovery
March 10, 2020
This week we are celebrating the release of the 250th version of our drug discovery software platform! I am so incredibly proud of the improvements our software team is constantly pushing out; it is the foundation that supports twoXAR’s dedication to rapidly identifying treatments for patients in need.
Our platform makes drug discovery and development faster and with fewer false positives. To build this platform, we use an approach that tightly couples scientists and software developers to make R&D faster, more accurate, and/or cheaper...read post here.
Andrew A. Radin, twoXAR CEO
February 18, 2020
I met Tim for the first time almost three years ago and I remember our meeting well. He furrowed his brow slightly as I explained the details on how our technology creates computational models of pathogenesis to derive new understanding of disease, and then identifies hits to test those new hypotheses within weeks instead of years. I’ve come to learn that the furrowed brow appears when the gears start turning in Tim’s head. And what exceptional gears they are... read post here.
Andrew A. Radin, twoXAR CEO
February 3, 2020
Today I received an email from an influencer in the life science community. Paraphrasing a bit, here’s what she said:
“We have reviewed nearly 400 companies in this space — so much going on! How are you differentiated from others?”
Rather than email her individually, I viewed this as the perfect opportunity to share how twoXAR Pharmaceuticals is different. Our work is like nothing else... read post here.
Read full blog at: twoxar.medium.com
EVENTS
National Academies of Science, Engineering, and Medicine (Virtual)
February 22, 2021
twoXAR Pharmaceuticals CEO Andrew A. Radin presents in a session on new technologies enabling discovery research.
MIT ILP (Digital)
January 27, 2021
twoXAR Pharmaceuticals CEO Andrew Radin presents at the MIT Startup Exchange Lightning Talk.
Digital
January 11-15, 2021
twoXAR Pharmaceuticals CEO Andrew Radin presents on the company's capabilities in discovering first-in-class small molecules.
CM Life Sciences (Digital)
December 3, 2020
twoXAR Pharmaceuticals CEO Andrew A. Radin joins a webinar hosted by CM Life Sciences to discuss harnessing AI in drug discovery.
EPPIC Global (Digital)
October 17, 2020
twoXAR Pharmaceuticals SVP Nonclinical R&D & Chemistry Anjali Pandey moderates a panel including twoXAR CEO Andrew Radin, along with representatives from Recursion Pharma, ATOM Consortium, and NuMedii.
MIT ILP (Digital)
October 16, 2020
twoXAR Pharmaceuticals CEO Andrew Radin presents on the company's capabilities in discovering first-in-class small molecules for oncology and more using AI.
FEATURE ARTICLES
Targeted Oncology
June 26, 2020
MEDIA MENTIONS
Andrew A. Radin, CEO - TEDMED 2016
WEBINARS, PODCASTS & VIDEOS
twoXAR Tutorials
December 2, 2020
SVP Nonclinical R&D & Chemistry, Anjali Pandey provides insight on what's next for twoXAR
twoXAR Tutorials
December 2, 2020
VP Discovery, Aaron Daugherty shares how we collaborate with our partners
twoXAR Tutorials
December 2, 2020
SVP R&D, Mark Eller discusses the role of AI in the drug discovery ecosystem
The Moneyball Medicine Podcast
September 14, 2020
twoXAR Pharmaceuticals SVP of R&D Mark Eller, Ph.D. joins host Harry Glorikian to discuss his journey from traditional pharma to believing in the power of AI.
The Moneyball Medicine Podcast
August 31, 2020
twoXAR Pharmaceuticals CEO Andrew A. Radin joins host Harry Glorikian to discuss the latest updates from twoXAR Pharmaceuticals.
Oncology Tube
August 28, 2020
twoXAR Fellow, Dr. Timothy Heuer discusses twoXAR's investigational cancer treatment TXR-311.
PUBLICATIONS & POSTERS
Isaac Hakim, Sana Mujahid, Aaron C. Daugherty, Anjali Pandey, Timothy S. Heuer
Isaac Hakim, Mei-Sze Chua, Wei Wei, Li Ma, Samuel So, Elizabeth Noblin, Sana Mujahid, Aaron C. Daugherty, and Timothy S. Heuer
Isaac Hakim, Sana Mujahid, Aaron C Daugherty and Timothy S Heuer
Isaac Hakim, Sana Mujahid, Aaron C Daugherty and Timothy S Heuer
Yen S Low, Aaron C Daugherty, Elizabeth A Schroeder, William Chen, Tina Seto, Susan Weber, Michael Lim, Trevor Hastie, Maya Mathur, Manisha Desai, Carl Farrington, Andrew A Radin, Marina Sirota, Pragati Kenkare, Caroline A Thompson, Peter P Yu, Scarlett L Gomez, George W Sledge Jr, Allison W Kurian, Nigam H Shah. Journal of the American Medical Informatics Association. EPub: December 9, 2016
Aaron C Daugherty, Carl Farrington, Isaac Hakin, Sana Mujahid, Elizabeth S Noblin, Andrew M Radin, Mei-Sze Chua, Mark Rabe, Guy Fernald, Daniel Ford, Marina Sirota, Laura Schaevitz, Andrew A Radin. bioRxiv 243998; doi: https://doi.org/10.1101/243998
Poster: An Integrative Bioinformatics Approach Identifies In Vivo Validated Drug Candidates with Novel Mechanisms of Action in Rheumatoid Arthritis
Aaron C Daugherty1, Carl Farrington1, Isaac Hakim1, Elizabeth S Noblin1, Andrew M Radin1, Mei-Sze Chua2, Mark Rabe3, Guy Fernald3, Daniel Ford3, Marina Sirota4, Laura Schaevitz3, Andrew A Radin1
1twoXAR, 2Stanford University School of Medicine, 3Vium, 4UCSF
© 2021 twoXAR, Incorporated | All Rights Reserved